Literature DB >> 8874070

Prevalence and clinical manifestations of Shiga toxin-producing Escherichia coli infections in Austrian children.

F Allerberger1, D Rossboth, M P Dierich, S Aleksic, H Schmidt, H Karch.   

Abstract

The prevalence and clinical manifestations of infections associated with Shiga toxin-producing Escherichia coli (STEC) among Austrian children were assessed. Stool samples from 280 pediatric patients were analyzed by enzyme immunoassay (EIA) for the presence of free fecal Shiga toxin (Stx) 1 and 2, and by culture on sorbitol MacConkey agar. Specimens testing positive by the EIA were subjected to a cytotoxicity assay, polymerase chain reaction analysis, and a colony hybridization test. Direct culture on MacConkey agar demonstrated the presence of three Escherichia coli O157:H7-positive stools. These were also positive by EIA and by the DNA-based methods. An additional six samples were positive by EIA, and in four of these, non-O157 STEC of serotypes O111H-, O146:H-, and O113:H53 could be isolated. Analysis of stools for a variety of enteric pathogens demonstrated that STEC was the third most common bacterial pathogen. The clinical manifestations of STEC infections were difficult to distinguish from those of infections caused by other enteric pathogens, as most patients presented with watery diarrhea. The median age of children with STEC infections was 27.6 months (range, 7 months to 5.75 years); children with Salmonella or Campylobacter infections were younger on average, while those with Rotavirus infections were older. This study demonstrated that although Escherichia coli O157:H7 could be identified with the same sensitivity by both EIA or agar-based methods, the identification of non-O157 STEC strains was enhanced by the use of EIA followed by colony hybridization. Analysis of overnight cultures from 53 STEC isolates revealed that all strains producing Stx1, Stx2, or Stx2c reacted in the EIA. However, culture supernatants from Stx2e-producing Escherichia coli O101 were negative in the EIA. Despite this disadvantage, the EIA is easy to perform and time efficient and can be recommended as a screening test for non-O157 STEC in children with diarrhea.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8874070     DOI: 10.1007/bf01709361

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  25 in total

Review 1.  Escherichia coli O157:H7 and the hemolytic-uremic syndrome.

Authors:  T G Boyce; D L Swerdlow; P M Griffin
Journal:  N Engl J Med       Date:  1995-08-10       Impact factor: 91.245

2.  Cloning and characterization of the eae gene of enterohaemorrhagic Escherichia coli O157:H7.

Authors:  J Yu; J B Kaper
Journal:  Mol Microbiol       Date:  1992-02       Impact factor: 3.501

3.  A biotyping scheme for Shiga-like (Vero) toxin-producing Escherichia coli O157 and a list of serological cross-reactions between O157 and other gram-negative bacteria.

Authors:  S Aleksić; H Karch; J Bockemühl
Journal:  Zentralbl Bakteriol       Date:  1992-01

4.  Serological and biochemical properties of Shiga-like toxin (verocytotoxin)-producing strains of Escherichia coli, other than O-group 157, from patients in Germany.

Authors:  J Bockemühl; S Aleksić; H Karch
Journal:  Zentralbl Bakteriol       Date:  1992-01

5.  Molecular detection of sorbitol-fermenting Escherichia coli O157 in patients with hemolytic-uremic syndrome.

Authors:  F Gunzer; H Böhm; H Rüssmann; M Bitzan; S Aleksic; H Karch
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

6.  Screening for Escherichia coli O157:H7--a nationwide survey of clinical laboratories.

Authors:  T G Boyce; A G Pemberton; J G Wells; P M Griffin
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

7.  Shiga-like toxin-producing Escherichia coli in Seattle children: a prospective study.

Authors:  T N Bokete; C M O'Callahan; C R Clausen; N M Tang; N Tran; S L Moseley; T R Fritsche; P I Tarr
Journal:  Gastroenterology       Date:  1993-12       Impact factor: 22.682

8.  Occurrence and phenotypic properties of verotoxin producing Escherichia coli in sporadic cases of gastroenteritis.

Authors:  A P Burnens; P Boss; F Orskov; I Orskov; U B Schaad; F Müller; R Heinzle; J Nicolet
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-07       Impact factor: 3.267

9.  Community outbreak of hemolytic uremic syndrome attributable to Escherichia coli O111:NM--South Australia 1995.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1995-07-28       Impact factor: 17.586

10.  Laboratory investigation of hemorrhagic colitis outbreaks associated with a rare Escherichia coli serotype.

Authors:  J G Wells; B R Davis; I K Wachsmuth; L W Riley; R S Remis; R Sokolow; G K Morris
Journal:  J Clin Microbiol       Date:  1983-09       Impact factor: 5.948

View more
  5 in total

1.  Sensitive detection of Escherichia coli O157:H7 in food and water by immunomagnetic separation and solid-phase laser cytometry.

Authors:  B H Pyle; S C Broadaway; G A McFeters
Journal:  Appl Environ Microbiol       Date:  1999-05       Impact factor: 4.792

2.  Application of a DNA hybridization-hydrophobic-grid membrane filter method for detection and isolation of verotoxigenic escherichia coli.

Authors:  E C Todd; R A Szabo; J M MacKenzie; A Martin; K Rahn; C Gyles; A Gao; D Alves; A J Yee
Journal:  Appl Environ Microbiol       Date:  1999-11       Impact factor: 4.792

Review 3.  Diarrheagenic Escherichia coli.

Authors:  J P Nataro; J B Kaper
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

4.  Etiology of acute gastroenteritis in three sentinel general practices, Austria 2007.

Authors:  S Huhulescu; R Kiss; M Brettlecker; R J Cerny; C Hess; G Wewalka; F Allerberger
Journal:  Infection       Date:  2008-12-03       Impact factor: 3.553

5.  Surveillance for Shiga toxin-producing Escherichia coli, Michigan, 2001-2005.

Authors:  Shannon D Manning; Robbie T Madera; William Schneider; Stephen E Dietrich; Walid Khalife; William Brown; Thomas S Whittam; Patricia Somsel; James T Rudrik
Journal:  Emerg Infect Dis       Date:  2007-02       Impact factor: 6.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.